Deanol Trials in Tardive Dyskinesia

  • D. E. Casey


Interest in the identification and treatment of movement disorders has greatly increased in recent years. As the knowledge of the biochemistry of neurotransmitters continues to develop, new approaches to treatment are being suggested. One trend of major interest has been the evaluation of the interaction of dopamine (DA) and acetylcholine (ACh) in tardive dyskinesia. In the past few years deanol, a putative precursor of ACh (Haubrich et al., 1975; Pfeiffer et al., 1957), has been used to study the role of cholinergic influences in this syndrome. Since the results with deanol have been conflicting, the purpose of this chapter is two-fold: to demonstrate a method of utilizing short-acting challenge drugs to develop a pharmacologic profile of tardive dyskinesia that may predict the response to deanol, and to summarize the available data in the limited number of clinical trials to determine the efficacy of deanol as a treatment for tardive dyskinesia.


Tardive Dyskinesia Neuroleptic Drug Placebo Period Mouth Movement Brain Acetylcholine 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Alpert, M., Diamond, F., and Friedhoff, A.J., 1976, Tomographic studies in tardive dyskinesia, PsychopharmacoL Bull 12: 5.PubMedGoogle Scholar
  2. Ansell, G.B., and Spanner, S., 1962, The effect of 2-dimethylaminoethanol on brain phospholipid metabolism, J. Neurochem. 9: 253.PubMedCrossRefGoogle Scholar
  3. Bird, D., and Aghajanian, G., 1975, Denervation supersensitivity in the cholinergic septohippocampal pathway: a microiontophoretic study, Brain Res. 100: 355.PubMedCrossRefGoogle Scholar
  4. Bjornstad, P., and Bremer, J., 1966, In vivo studies on pathways for the biosynthesis of lecithin in the rat, J. Lipid Res. 7: 38.Google Scholar
  5. Bockenheimer, S., and Lucius,G., 1976, Zur Therapie mit Dimethylaminoethanol(Deanol) bei neuroleptikainduzierten extrapyramidal Hyperkinesen, Arch. Psychiatr. Nervenkr. 222: 69.PubMedCrossRefGoogle Scholar
  6. Bremer, J., Figard, P.H., and Greenberg, D.M., 1960, The biosynthesis of choline and its relation to phospholipid metabolism, Biochim. Biophys. Acta 43: 477.CrossRefGoogle Scholar
  7. Burt, D.R., Creese, I., and Snyder, S.H., 1977, Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain, Science 196: 326.PubMedCrossRefGoogle Scholar
  8. Carroll, B.J., Curtis, G.C., and Kokmen, E., 1977, Paradoxical response to dopamine agonists in tardive dyskinesia, Am. J. Psychiatry 134: 185.Google Scholar
  9. Casey, D.E., 1976, Tardive dyskinesia: are there subtypes? N. Engl J. Med. 259: 1078.Google Scholar
  10. Casey, D.E., 1977, Deanol in the management of involuntary movement disorders: a review, Dis. Nerv. Syst. 38(2): 1.Google Scholar
  11. Casey, D.E., and Denney, D., 1974, Dimethylaminoethanol in tardive dyskinesia, 1974, N. Engl. J. Med. 291: 191.CrossRefGoogle Scholar
  12. Casey, D.E., and Denney, D., 1975, Deanol in the treatment of tardive dyskinesia, Am. J. Psychiatry 752: 864.Google Scholar
  13. Casey, D.E., and Denney, D., 1977, Pharmacological characterization of tardive dyskinesia, Psychopharmacology 54: 1.PubMedCrossRefGoogle Scholar
  14. Claveria, L.E., Teychenne, P.F., Calne, D.B., Haskayne, L., Petrie, A., Pallis, C.A., and Lodge-Patch, I.C., 1975, Tardive dyskinesia treated with pimozide, J. Neurol. Sci. 24: 393.PubMedCrossRefGoogle Scholar
  15. Cole, J.O., Gardos, G., and Granacher, R., 1976, Drug evaluations in tardive dyskinesia: papaverine and deanol, presented at the 129th annual meeting of the American Psychiatric Association, Miami Beach, Florida.Google Scholar
  16. Cools, A.R., and VanRossum, J.M., 1976, Excitation-mediating and inhibition-mediating dopamine-receptors: a new concept towards a better understanding of the electrophysiological, biochemical, pharmacological, functional, and clinical data, Psychopharmacologia 45: 243.PubMedCrossRefGoogle Scholar
  17. Crane, G.E., 1973, Persistent dyskinesia, J. Psychiatry 722: 395.CrossRefGoogle Scholar
  18. Crane, G.E., 1975, Deanol for tardive dyskinesia, N. Engl. J. Med. 292: 926.CrossRefGoogle Scholar
  19. Crane, G.E., and Smeets, R.A., 1974, Tardive dyskinesia and drug therapy in geriatric patients, Arch. Gen. Psychiatry 30: 341.PubMedGoogle Scholar
  20. Curran, D.J., Nagaswami, S., and Mohan, K.J., 1975, Treatment of phenothiazine-induced bulbar persistent dyskinesia with deanol acetamidobenzoate, Dis. Nerv. Syst. 36: 11.Google Scholar
  21. Danysz, A., Kocmierska-Grodzka, D., Kostro, B., Polocki, B., and Kruszewska, J., 1967, Pharmacological properties of 2-dimethylaminoethanol (bimanol-DMAE), Diss. Pharm. Pharmacol 19: 469.Google Scholar
  22. Davis, K.L., Berger, P.A., and Hollister, L.E., 1975, Choline for tardive dyskinesia, N. Engl J. Med. 293: 152.PubMedGoogle Scholar
  23. Davis, K.L., Hollister, L.E., Barchas, J.D., and Berger, P.A., 1976, Choline in tardive dyskinesia and Huntington’s disease, Life Sci. 19: 1501.CrossRefGoogle Scholar
  24. Davis, K.L., Berger, P.A., Hollister, L.E., and De Fraites, 1978, Physostigmine in mania, Arch. Gen. Psychiatry 55: 119.Google Scholar
  25. Denham, J., and Carrick, D.J., 1961, Therapeutic value of thioproperazine and the importance of the associated neurological disturbances, J. Ment. Sci 107: 326.PubMedGoogle Scholar
  26. Denney, D., and Casey, D.E., 1975, An objective method for measuring dyskinetic movements in tardive dyskinesia, Electroencephalogr. Clin. Neurophysiol. 38: 645.PubMedCrossRefGoogle Scholar
  27. DeSilva, L., and Huang, C.Y., 1975, Deanol in tardive dyskinesia, Br. Med. J. 3: 466.CrossRefGoogle Scholar
  28. Dormard, Y., Levron, J.C., and LeFur, J.M., 1975, Pharmacokinetic study of maleate acid of 2-(N,N-dimethylaminoethanol-14C1)cyclohexylpropionate (cyprodenate) and of N,N-dimethylaminoethanol-14C1 in animals. II. Study and identification of the metabolites of 14C-cyprodenate ana 14C-dimethylaminoethanol in animals, Arzneim. Forsch. 25: 201.Google Scholar
  29. DuVigneaud, V., Chandler, S.P., Simmonds, S., Moyer, A.W., and Cohn, M., 1946, The role of dimethyl- and monomethylaminoethanol in transmethylation reactions in vivo, J. Biol. Chem. 164: 603.Google Scholar
  30. Escobar, J.I., and Kemp, K.F., 1975, Dimethylaminoethanol for tardive dyskinesia, TV. Engl. J. Med. 292: 317.CrossRefGoogle Scholar
  31. Fann, W.E., Lake, C.R., Gerber, C.J., and McKenzie, G.M., 1974, Cholinergic suppression of tardive dyskinesia, Psychopharmacologia 37: 101.PubMedCrossRefGoogle Scholar
  32. Fann, W.E., Sullivan, J.L., Miller, R.D., and McKenzie, G.M., 1975, Deanol in tardive dyskinesia: a preliminary report, Psychopharmacologia 42: 135.PubMedCrossRefGoogle Scholar
  33. Freeman, J.J., and Jenden, D.J., 1976, The source of choline for acetylcholine synthesis in brain, Life Sci. 19: 949.PubMedCrossRefGoogle Scholar
  34. Gardos, G., Cole, J.O., and Sniffen, C., 1976, An evaluation of papaverine in tardive dyskinesia, J. Clin. Pharmacol. 76: 304.Google Scholar
  35. Gerlach, J., Reisby, N., and Randrup, A., 1974, Dopaminergic hypersensitivity and cholinergic hypofunction in the pathophysiology of tardive dyskinesia, Psychopharmacologia 34: 21.PubMedCrossRefGoogle Scholar
  36. Goldberg, A.M., and Silbergeld, E.K., 1974, Neurochemical aspects of lead-induced hyperactivity, Trans. Amer. Soc. Neurochem. 5: 185.Google Scholar
  37. Granacher, R.P., Baldessarini, R.J., and Cole, J.O., 1975, Deanol for tardive dyskinesia, N. Engl. J. Med. 292: 926.CrossRefGoogle Scholar
  38. Growdon, J.H., Hirsch, M.J., Wurtman, R.J., and Wiener, W., 1977, Oral choline administration to patients with tardive dyskinesia, N. Engl. J. Med. 297: 524.PubMedCrossRefGoogle Scholar
  39. Hanin, I., and Costa, E., 1976, Approaches used to estimate brain acetylcholine turnover rate in vivo; effects of drugs on brain acetylcholine turnover rate, in “Biology of Cholinergic Function” (A. Goldberg and I. Hanin, eds.), pp. 355–377, Raven Press, New York.Google Scholar
  40. Haubrich, D.R., Wang, P.F.L., Clody, D.E., and Wedeking, P.W., 1975, Increase in rat brain acetylcholine induced by choline or deanol, Life Sei. 17: 915.CrossRefGoogle Scholar
  41. Hippius, H., and Logemann, G., 1970, Zur Wirkung von Dioxyphenylalanin (L-DOPA) auf extrapyramidalmotorische Hyperkineses nach langfristiger neuroleptische Therapie, Arzneim. Forsch. 20: 894.Google Scholar
  42. Jacobson, G., Baldessarini, R.J., and Manschreck, T., 1974, Tardive dyskinesia associated with haloperidol, Am. J. Psychiatry 131: 910.PubMedGoogle Scholar
  43. Janowsky, D.S., Davis, J.M., El-Yousef, M.K., and Sekerke, H.J., 1972, A cholinergic- adrenergic hypothesis of mania and depression, Lancet 2 (7778): 632.Google Scholar
  44. Janowsky, D.S., El-Yousef, M.K., Davis, J.M., and Sekerke, H.J., 1973, Parasympathetic suppression of manic symptoms by physostigmine, Arch. Gen. Psychiatry 28: 542.PubMedGoogle Scholar
  45. Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P., and Villeneuve, R., 1976a, Epidemiology of tardive dyskinesia: Part I, Dis. Nerv. Syst. 37: 210.PubMedGoogle Scholar
  46. Jus, A., Pineau, R., Lachance, R., Pelchat, G., Jus, K., Pires, P., and Villeneuve, R., 1976b, Epidemiology of tardive dyskinesia: Part II, Dis. Nerv. Syst. 37: 257.PubMedGoogle Scholar
  47. Kazamatsuri, H., Chien, C., and Cole, J.O., 1972a, The treatment of tardive dyskinesia. I. Clinical efficacy of a dopamine-depleting agent, tetrabenazine, Arch. Gen. Psychiatry 27: 95.PubMedGoogle Scholar
  48. Kazamatsuri, H., Chien, C., and Cole, J.O., 1972b, The treatment of tardive dyskinesia. II. Short-term efficacy of dopamine-blocking agents haloperidol and thiopropazate, Arch. Gen. Psychiatry 27: 100.PubMedGoogle Scholar
  49. Kazamatsuri, H., Chien, C.P., and Cole, J.O., 1973, Long-term treatment of tardive dyskinesia with haloperidol and tetrabenazine, Am. J. Psychiatry 130: 419.Google Scholar
  50. Klawans, H.L., 1973, The pharmacology of tardive dyskinesia, Am. J. Psychiatry 130: 82.PubMedGoogle Scholar
  51. Klawans, H.L., and McKendall, R., 1971, Observations on the effect of L-DOPA on tardive lingual-facial-buccal dyskinesia, J. Neurol Sci. 74: 189.CrossRefGoogle Scholar
  52. Klawans, H.L., and Rubovits, R., 1972, An experimental model of tardive dyskinesia, J. Neural Transm. 33: 235.PubMedCrossRefGoogle Scholar
  53. Klawans, H.L., and Rubovits, R., 1974, Effect of cholinergic and anticholinergic agents on tardive dyskinesia, J. Neurol. Neurosurg. Psychiatry 27: 941.CrossRefGoogle Scholar
  54. Klawans, H.L., Topel, J.L., and Bergen, D., 1975, Deanol in the treatment of L-DOPA- induced dyskinesias, Neurology 25: 290.PubMedGoogle Scholar
  55. Kumar, B.B., 1976, Treatment of tardive dyskinesia with deanol, Am. J. Psychiatry 133: 978.Google Scholar
  56. Lai, S., 1974, Comparison of thiopropazate and trifluoperazine on oral dyskinesia — a double-blind study, Curr. Ther. Res. 16: 990.Google Scholar
  57. Laterre, E.C., and Fortemps, E., 1975, Deanol in spontaneous and induced dyskinesias, Lancet 1 (7919): 1301.Google Scholar
  58. Lewander, T., Joh, T.H., and Reis, D.J., 1975, Prolonged activation of tyrosine hydroxylase in noradrenergic neurons of rat brain by cholinergic stimulation, Nature 258: 440.PubMedCrossRefGoogle Scholar
  59. McLean, P., and Casey, D.E., 1978, Tardive dyskinesia in an adolescent, Am. J. Psychiatry 135: 969.PubMedGoogle Scholar
  60. Mehta, D., Mehta, S., and Mathew, P., 1976, Failure of deanol in treating tardive dyskinesia, Am. J. Psychiatry 133: 1461.Google Scholar
  61. Miller, E., 1974, Deanol: a solution for tardive dyskinesia? N. Engl J. Med. 291: 196.Google Scholar
  62. Miller, E., 1976, Effectiveness of deanol on L-DOPA-induced dyskinesias: a placebo-controlled double-blind crossover study, in “Advances in Parkinsonism” ( W. Birkmayer, and O. Hornykiewics, eds.), pp. 582–590, Hoffmann-LaRoche, Basle, Switzerland.Google Scholar
  63. Moline, R., 1975, Atypical dyskinesia, Am. J. Psychiatry 132: 534.PubMedGoogle Scholar
  64. Nesse, R., and Carroll, B.J., 1976, Cholinergic side-effects associated with deanol, Lancet 2(7975): 50.Google Scholar
  65. Pepeu, G., Freedman, D.X., and Giarman, N.J., 1960, Biochemical and pharmacological studies of dimethylaminoethanol (deanol), J. Pharmacol Exp. Ther. 129: 291.PubMedGoogle Scholar
  66. Pfeiffer, C.C., Jenney, E.H., Gallacher, W., Smith, R.P., Bevan, J., Killam, E.K., Killam, K.F., and Blackmore, W., 1957, Stimulant effect of 2-dimethylaminoethanol - possible precursor of brain acetylcholine, Science 126: 610.PubMedCrossRefGoogle Scholar
  67. Quitkin, F., Rifkin, A., Gochfeld, L., and Klein, D.F., 1977, Tardive dyskinesia: are first signs reversible? Am. J. Psychiatry 134: 84.PubMedGoogle Scholar
  68. Sarwer-Foner, G.J., 1960, Recognition and management of drug-induced extrapyramidal reactions and “paradoxical” behavioral reactions in psychiatry, Can. Med. Assoc. J. 83: 312.PubMedGoogle Scholar
  69. Sato, S., Daly, R., and Peters, H., 1971, Reserpine therapy of phenothiazine-induced dyskinesia, Dis. Nerv. Syst. 32: 680.PubMedGoogle Scholar
  70. Scheel-Kruger, J., and Randrup, A., 1968, Pharmacological evidence for a cholinergic mechanism in brain involved in a special stereotyped behavior of reserpined rats, Br. J. Pharmacol 34: 211.Google Scholar
  71. Schiorring, E., and Randrup, A., 1968, Paradoxical stereotyped activity of reserpined rats, lnt. J. Neuropharmacol. 7: 71.CrossRefGoogle Scholar
  72. Simpson, G.M., 1973, Tardive dyskinesia, J. Psychiatry 122: 618.CrossRefGoogle Scholar
  73. Simpson, G.M., Voitashevsky, A., Young, M.A., and Lee, H.J., 1977, Deanol in the treatment of tardive dyskinesia, Psychopharmacology 52: 251.CrossRefGoogle Scholar
  74. Singer, K., and Cheng, M.N., 1971, Thiopropazate HCL in persistent dyskinesia, Br. Med. J. 4: 22.PubMedCrossRefGoogle Scholar
  75. Smith, R.C., Tamminga, C., Haraszti, J., Pandey, G.N., and Davis, J.M., 1977, Effects of dopamine agonists in tardive dyskinesia, Am. J. Psychiatry 134: 163.Google Scholar
  76. Snyder, S., Greenberg, D., and Yamamura, H., 1974, Antischizophrenic drugs and brain cholinergic receptors, Arch. Gen. Psychiatry 31: 58.PubMedGoogle Scholar
  77. Tamminga, C., Smith, R.C., Chang, S., Haraszti, J.S., and Davis, J.M., 1976, Depression associated with oral choline, Lancet 2(7991): 905.Google Scholar
  78. Tamminga, C., Smith, R.C., Ericksen, S.E., Chang, S., and Davis, J.M., 1977, Cholinergic influences in tardive dyskinesia, Am. J. Psychiatry 134: 169.Google Scholar
  79. Tarsy, D., and Baldessarini, R.J., 1976, The tardive dyskinesia syndrome, in “Clinical Neuropharmacology” ( H.L. Klawans, ed.), Vol. 1, pp. 29–61, Raven Press, New York.Google Scholar
  80. Tarsy, D., Leopold, N., and Sax, D.S., 1974, Physostigmine in choreiform movement disorders.Neurology 24: 28.Google Scholar
  81. Uhrbrand, L., and Faurbye, A., 1960, Reversible and irreversible dyskinesia after treatment with perphenazine, chlorpromazine, reserpine and electroconvulsive therapy, Psychopharmacologia 1: 408.CrossRefGoogle Scholar
  82. Ulus, I.H., and Wurtman, R.J., 1976, Choline administration: activation of tyrosine hydroxylase in dopaminergic neurons of rat brain, Science 194: 1060.PubMedCrossRefGoogle Scholar
  83. Walker, J.E., Hoehn, M., Sears, E., and Lewis, J., 1973, Dimethylaminoethanol in Huntington’s chorea, Lancet 1(7818): 1512.Google Scholar
  84. Weiner, W.J., Kanapa, D.J., and Klawans, H.L., 1976, The effect of dimethylaminoethanol (deanol) on amphetamine-induced stereotyped behavior, Life Sci. 19: 1311.CrossRefGoogle Scholar
  85. Widroe, H.J., and Heisler, S., 1976, Treatment of tardive dyskinesia, Dis. Nerv. Syst. 37: 162.PubMedGoogle Scholar
  86. Zahniser, N.R., and Hanin, I., 1976, Deanol and the cholinergic system: a gas chromatographic evaluation, Fed. Proc. 55: 801.Google Scholar
  87. Zahniser, N.R., Chou, D., and Hanin, I., 1977, Is 2-dimethylaminoethanol (deanol) indeed a precursor of brain acetylcholine? A gas chromatographic evaluation, J. Pharmacol. Exp. Ther. 200: 545.PubMedGoogle Scholar

Copyright information

© Plenum Press, New York 1979

Authors and Affiliations

  • D. E. Casey
    • 1
    • 2
  1. 1.Departments of Medical Research and Psychiatry Portland VA HospitalUSA
  2. 2.Department of PsychiatryUniversity of Oregon Health Sciences CenterPortlandUSA

Personalised recommendations